Helix Acquisition II, a new SPAC formed by Cormorant Asset Management, registered to offer 10 million shares at $10 each. No warrants are included.
Cormorant has “indicated the interest” of buying 2.5 million shares as well as potentially investing $35 million in a private placement that would occur with the closing of a merger with the SPAC. There are no formal agreements in place for these possible investments. Cormorant is a life sciences-focused investment firm with over $2 billion AUM.
Helix II intends to focus on the healthcare industry.
The SPAC intends to apply for a listing on the Nasdaq under the symbol HLXB.
Leerink Partners is sole bookrunning manager for the offering. Read more.